ArticleClinical & translational immunology2021
IFN-γ facilitates liver fibrogenesis by CD161
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic CholangiocarcinomaFrontiers in immunology · 2022Trial
- Protective effect of cannabinoid type 2 receptor agonist (JWH-133) against hepatotoxicity induced by Prangos ferulacea Lindl. extract.Experimental physiology · 2026Article
- Elevated Peripheral CD161ACR open rheumatology · 2026Article
- Differentiated associations of inflammatory indices with laboratory-defined organ injury/involvement and hospitalization length in pediatric respiratory tract infections.Frontiers in pediatrics · 2026Article
- CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment.Frontiers in medicine · 2026Article
- Clinical characteristics of patients with hepatitis and cirrhosis and the construction of a prediction model.World journal of hepatology · 2025Article
- Immunobiology roles of the human CD161 receptor in T cells.Frontiers in immunology · 2025Review
- Intrahepatic CD161Immunity, inflammation and disease · 2025Article
- Construction and validation of a joint diagnosis model based on random forest and artificial intelligence network for hepatitis B-related hepatocellular carcinoma.Translational cancer research · 2024Article
- The Role of Interleukins in HBV Infection: A Narrative Review.Journal of personalized medicine · 2023Review
- IFN-γ: A Crucial Player in the Fight Against HBV Infection?Immune network · 2023Review
- A TNature aging · 2023Article
- Insights into the impact of hepatitis B virus on hepatic stellate cell activation.Cell communication and signaling : CCS · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to determine the role of CD161
methodsA total of 94 patients with chronic hepatitis B (CHB), 73 with liver cirrhosis (LC) and 28 healthy controls were enrolled to determine frequency, cytokine production and chemokine receptor expression of circulating CD161
resultsCD161
conclusionsIn chronic HBV infection, CD161
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.